Waystar became one of the strongest company-specific gainers on September 15 after a Reuters report said the healthcare software provider is exploring strategic options, including a possible sale.
The shares rose more than 8% after the report and finished the session up 7.1%.
The company is worth about $5.2 billion after the move.
The reported process comes at an interesting time for software valuations. Waystar has strong operating growth, but the broader software sector has been under pressure as investors debate whether artificial intelligence will strengthen incumbents or disrupt traditional software categories.
A potential sale would test how private-equity and strategic buyers value a healthcare software business in that environment.
What Has Been Reported
Reuters reported that Waystar has hired Evercore to advise on strategic options.
Barclays is also advising the company, according to a person familiar with the matter.
The process is described as early stage.
That is important: a sale may not happen.
Waystar declined to comment, Barclays declined to comment, and Evercore did not immediately respond to Reuters.
So the confirmed market-moving information is that multiple sources say the company is exploring options. There is no announced transaction, no confirmed buyer and no agreed price.
Why Waystar Could Attract Interest
Waystar operates software used by hospitals and doctors to manage healthcare payments and administrative workflows.
The company serves more than 30,000 clients, representing more than 1 million providers.
Its platform processes over 7.5 billion healthcare payment transactions annually, including more than $2.4 trillion in gross claims, and touches roughly 60% of U.S. patients.
That scale creates several features buyers may value.
The software is embedded in mission-critical healthcare workflows.
The business handles large volumes of proprietary transaction data.
Healthcare payments are complex and difficult to replace.
And automation can create measurable return on investment for customers.
Waystar’s Recent Financial Performance
The latest reported quarter was not weak.
Second-quarter 2026 revenue reached $319.7 million, up 18% year over year.
Net income was $40.9 million.
Adjusted EBITDA margin reached 43%.
Waystar also raised its 2026 revenue and adjusted EBITDA guidance.
Those figures matter because they show the reported sale exploration is not simply a distressed-company story.
The company is growing and profitable.
The valuation debate is more about what multiple that growth deserves in an AI-disrupted software market.
Why AI Is Part of the Story
Healthcare administrative software is both exposed to AI and positioned to benefit from it.
On one side, new AI systems can automate tasks that traditional software companies previously charged customers to manage through established interfaces.
That creates concern that AI could reduce the value of some legacy software workflows.
On the other side, Waystar already uses automation and AI capabilities to improve healthcare payment processes.
A buyer could therefore view the company as an asset that becomes more valuable as automation spreads rather than less valuable.
The market has not resolved that debate.
Why a Private Buyer Might Be Interested
Waystar has a history with private capital.
It was created in 2017 through the combination of Zirmed and Navicure and was taken public in 2024 by investors including EQT, the Canada Pension Plan Investment Board and Bain Capital.
EQT remains the largest shareholder with about a 13% stake, followed by CPPIB at roughly 10%.
A private buyer could potentially value the company on long-term cash flow and strategic position without worrying as much about short-term public-market multiple compression.
That does not mean a take-private is likely. It simply explains why the structure could make sense.
Could a Strategic Buyer Emerge?
Possibly, but investors should treat any specific buyer name as speculation until a company confirms interest.
A strategic acquirer would need to believe Waystar’s healthcare data, payment network and software relationships are worth more inside a larger platform than as a standalone business.
Potential synergies could include distribution, cross-selling, cloud infrastructure or deeper automation.
But regulatory review, integration risk and price would all matter.
Why Financing Conditions Matter to a Sale
The reported process comes at a difficult moment for leveraged transactions. Treasury yields are high and credit markets are demanding more return. A potential buyer therefore has to make the economics work with a higher cost of debt than would have been available in a low-rate environment.
That can reduce the price financial buyers are willing to pay, even when the underlying company is performing well. It also increases the relative advantage of strategic buyers that can finance a transaction from their own balance sheet and justify a higher price through operating synergies.
Why the Stock Is Still Below Its Old Highs
Waystar shares had lost nearly a quarter of their market value in 2026 through September 14.
The stock had previously reached a 2025 peak around $45.
That decline reflects broader software-market pressure as investors reassess how AI will affect pricing power and competitive moats.
A sale process can create a new valuation reference point.
It can reveal whether strategic or financial buyers are willing to pay more than public investors.
What Could Derail a Deal
The process may simply end without a transaction.
Potential buyers may disagree with the valuation.
Financing costs are high because Treasury yields have risen.
Private-equity returns become harder to justify when debt is expensive.
Strategic buyers may face integration concerns.
And Waystar’s board may decide remaining public creates more long-term value.
Those risks explain why the stock does not automatically trade as if a takeover is certain.
What to Watch Next
Watch for an official Waystar statement or SEC filing.
Watch whether serious bidders emerge.
Watch the spread between Waystar’s market value and any reported potential deal valuation.
Also keep following operating results. If revenue continues growing near the current pace and margins remain strong, the company has more negotiating leverage.
The key question is:
Will the reported process produce a real transaction, or has the market simply received a reminder that Waystar’s healthcare-payment platform may be worth more than its recent public-market valuation implied?